Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KHK | P50053 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865892 | 0.90 | HPGD (0.54) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865834 | 0.88 | HPGD (0.46) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865865 | 0.88 | HPGD (0.54) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865905 | 0.88 | TP53 (0.48) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865939 | 0.87 | HPGD (0.45) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865906 | 0.85 | KHK (0.44) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865916 | 0.85 | HPGD (0.46) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865874 | 0.84 | KHK (0.62) | HPGDALDH1A1TSHRHTTKHK | |
| SCHEMBL13865825 | 0.84 | PDE9A (0.50) | HPGDALDH1A1TSHRHTT | |
| SCHEMBL13865846 | 0.83 | KHK (0.48) | HPGDALDH1A1TSHRHTTKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | HPGD 132/4885ALDH1A1 240/4885TSHR 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.